Table 4. Clinical outcomes for NCR group vs. CLR group at one year follow-up.

Adverse Events	NCR group (n = 375)	CLR group		P-value
		Ticagrelor group (n = 60)	Clopidogrel group (n = 240)
Data are presented as n (%). MACCEs: major adverse cardiac and cerebrovascular event, includes cardiac death, stent thrombosis, repeat revascularization, MI and stroke; MI: myocardial infarction. aP < 0.05 vs. NCLR group, bP < 0.05 vs. Ticagrelor group, cP < 0.05 vs. clopidogrel group.
All-cause death	5 (1.3%)	1 (1.7%)	7 (2.9%)	0.390
MACCEs	36b,c (9.6%)	7a,c (11.7%)	53a,b (22.1%)	0.000
Cardiac death	5(1.3%)	1(1.7%)	4(1.7%)	0.939
Stent thrombosis	10b,c (2.7%)	3a,c (5.0%)	19a,b (7.9%)	0.013
MI	9b,c (2.4%)	2a,c (3.3%)	16a,b (6.7%)	0.035
Repeat revascularization	11 (2.9%)	1 (1.7%)	12 (5.0%)	0.283
Stroke	1 (0.3%)	0 (-)	2 (0.8%)	0.473
Massive bleeding	5 (1.3%)	1 (1.7%)	3 (1.3%)	0.970
Moderate bleeding	11 (2.9%)	3 (5.0%)	9 (3.8%)	0.685
Small bleeding	28 (7.5%)	7 (11.7%)	19 (7.9%)	0.571